Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.” Their mean rating for Regeneron stock is 2.58, and their target price is $426.05, implying a 12.8% upside for the stock based on its December 10 closing price of $377.59.
In comparison, peers Amgen (AMGN), Biogen (BIIB), and Johnson & Johnson (JNJ) have received mean ratings of 2.33, 2.03, and 2.32, respectively, from analysts, and target prices of $204.80, $388.35, and $148.11.
Regeneron’s current ratio, which shows how effectively it can meet its short-term obligations, is 4.0x. In comparison, Amgen’s, Biogen’s, and Johnson & Johnson’s are 3.10x, 2.70x, and 1.70x, respectively.
In fiscal 2018 and 2019, Regeneron’s free cash flow is expected to be $1.98 billion and $2.27 billion, respectively, compared with $1.03 billion in fiscal 2017. Its price-to-free-cash-flow ratio is 25.25x, while Amgen’s, Biogen’s, and Johnson & Johnson’s ratios are 18.51x, 11.43x, and 42.81x, respectively.